Optic disc and retinal microvasculopathy after high-dose chemotherapy and autologous hematopoietic progenitor cell support

Bone Marrow Transplantation

Volumn 24, Issue 7, 1999, Pages 785-792

  Johnson, D W ^a   Cagnoni, P J ^a   Schossau, T M ^a   Stemmer, S M ^a   Grayeb, D E M ^a   Baron, A E ^a   Shpall, E J ^a   Bearman, S I ^a   McDermitt, J ^a   Jones, R B ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Autologous transplant; Breast cancer; Microvasculopathy

Indexed keywords

CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER; CANCER COMBINATION CHEMOTHERAPY; EDEMA; EYE TOXICITY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; OPTIC DISK ANOMALY; PRIORITY JOURNAL; RETINA DISEASE; RETINA HEMORRHAGE; SUBCUTANEOUS DRUG ADMINISTRATION; VISUAL IMPAIRMENT;

EID: 0032882407     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701913     Document Type: Article

References (16)

1. Coskuncan NM, Jabs DA, Dunn JP et al. The eye in bone marrow transplantation. VI. Retinal complications. Arch Ophthalmol 1994; 112: 372-379.
2. Khawly JA, Rubin P, Petros WP et al. Retinopathy and optic neuropathy in bone marrow transplantation for breast cancer. Ophthalmology 1996; 103: 87-95.
3. Jones RB, Matthes S, Shpall EJ et al. Acute lung injury following high-dose cyclophosphamide, cisplatin and carmustine with autologous bone marrow support: pharmacodynamic evaluation of carmustine. J Natl Cancer Inst 1993; 85: 640-647.
4. Deicas R, Street DA, Javitt JC. Assessment of visual acuity via a telephone interview. Arch Ophthalmol 1992; 110: 1279-1282.
5. Bernauer W, Gratwohl A, Keller A, Daicker B. Microvasculopathy in the ocular fundus after bone marrow transplantation. Ann Intern Med 1991; 115: 925-930.
6. Hirst LW, Jabs DA, Tutschka PJ et al. The eye in bone marrow transplantation. I. Clinical study. Arch Ophthalmol 1983; 101: 580-584.
7. Vogler WR, Winton EF, Heffner LT et al. Ophthalmological and other toxicities related to cytosine arabinoside and total body radiation as preparative regimen for bone marrow transplantation. Bone Marrow Transplant 1990; 6: 405-409.
8. Gloor B, Gratwohl A, Hahn H et al. Multiple cotton wool spots following bone marrow transplantation for treatment of acute lymphatic leukaemia. Br J Ophthalmol 1985; 69: 320-325.
9. Miller DF, Bay JW, Lederman RJ et al. Ocular and orbital toxicity following intracarotid injection of BCNU (carmustine) and cisplatin for malignant gliomas. Ophthalmology 1985; 92: 402-406.
10. Shingleton BJ, Bienfang DC, Albert DM et al. Ocular toxicity associated with high dose carmustine. Arch Ophthalmol 1982; 100: 1766-1772.
11. McLennan R, Taylor HR. Optic neuroretinitis in association with BCNU and procarbazine therapy. Med Pediatr Oncol 1978; 4: 43-48.
12. Wilding G, Caruso R, Lawrence TS et al. Retinal toxicity after high-dose cisplatin therapy. J Clin Oncol 1985; 3: 1683-1689.
13. Ostrow S, Hahn D, Wiernik PH, Richards RD. Ophthalmologic toxicity after cis-dichlorodiammineplatinum(II) therapy. Cancer Treat Rep 1978; 62: 1591-1594.
14. Urba S, Forastiere AA. Retrobulbar neuritis in a patient treated with intraarterial cisplatin for head and neck cancer. Cancer 1988; 62: 2094-2097.
15. Capri G, Munzone E, Tarenzi E et al. Optic nerve disturbances: a new form of paclitaxel neurotoxicity. J Natl Cancer Inst 1994; 86: 1099-1101.
16. Armitage JO. Bone marrow transplantation. New Engl J Med 1994; 330: 827-838.